ClinicalTrials.gg
CompletedNCT03284411Updated Apr 15, 2020Results posted

Spinal Cord Stimulation (SCS) Dosing Study

A Phase 4 interventional study of Spinal Cord Stimulation in Back Pain and Leg Pain, sponsored by MedtronicNeuro. Completed at 10 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.

Sponsored by MedtronicNeuro (part of Medtronic) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Back Pain by Medtronic — none open to participants now, none under way, none of them phase 3. Back Pain · Medtronic.

Enrollment
10th of 10
30 · median 166
Started
2017
with 1 other
Phase 4
5 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Back Pain by Medtronic, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2017, is one of 5 in phase 4, and was the 8th registered.

Back Pain

729 studies on the registry are indexed under Back Pain; 109 are open to participants now.

Browse Back Pain studies →

Open to participants now

None of the 11 studies in Back Pain by Medtronic is open now. The open studies under Back Pain, anywhere →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Back Pain by Medtronic as a file.
02

Study summary

This study characterized the effects of amplitude on subject satisfaction and pain relief in subjects being treated by SCS.

Read the detailed description

This feasibility study assessed the following outcomes:

  • Patient satisfaction
  • VAS pain scores
03

Conditions studied

  • Back Pain
  • Leg Pain

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 22 years of age or older
  2. Implanted with a RestoreSensor system (for back and leg pain) for at least 1 month
  3. Has approproate SCS settings
  4. Willing and able to provide signed and dated
  5. Capable of comprehending and consenting in English
  6. Capable of getting into the supine and sitting positions
  7. Willing and able to comply with all study procedures and visits
  8. On stable (no change in dose, route, or frequency) prescribed pain medications

Exclusion criteria

Exclusion Criteria:

  1. Implanted with leads for peripheral nerve stimulation or an implantable intrathecal drug delivery system
  2. Had a pain-related surgery in the previous 1 month of enrollment or the intent to undergo surgery during the period of the study
  3. Implanted with quadripolar lead
  4. Currently enrolled or planning to enroll in a potentially confounding clinical study during the course of the study
  5. Pregnant or is of and unwilling to use a medically acceptable form of during the study
  6. Has untreated major psychiatric comorbidity
  7. Has serious drug-related behavioral issues
  8. Has unresolved major issues of secondary gain
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Spinal Cord Stimulation

    Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude

    Device: Spinal Cord Stimulation

Interventions

  • DeviceSpinal Cord Stimulation

    Programming

06

What researchers measure

Primary outcomes

  1. SCS Therapy Satisfaction

    To characterize the effect of four different amplitude settings on baseline SCS therapy satisfaction. At each follow-up visit, the following question was asked to measure satisfaction: "Overall how satisfied or unsatisfied are you with this therapy?". The response choices were as follows: "very satisfied", "somewhat satisfied", "neutral", "somewhat unsatisfied", "very unsatisfied". Each subject was considered to have maintained their baseline SCS therapy satisfaction if they selected the response "very satisfied", "somewhat satisfied", or "neutral", otherwise they were considered dissatisfied with the therapy. The first visit in which each subject reported dissatisfaction of the therapy was recorded. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained each subject's therapy satisfaction. The frequency and percentage of subjects' that maintained baseline satisfaction were reported at each amplitude level.

    Time frame: 8 weeks

Secondary outcomes

  1. Number of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)

    To characterize the effect of four different amplitude settings on baseline pain relief. During each follow-up period the VAS pain score was recorded once a day, on a multi-day diary, where subjects rated their pain by making a vertical slash mark through the 0-10 cm line that best described their pain during the last 24 hours, with 0 = No pain and 10 = Worst pain imaginable. The higher VAS pain score represented worse pain. The average VAS pain scores from the last 3 days of the diary prior to the scheduled visit was used for analysis. Each subject was considered to have maintained their baseline pain if there was less than a 2 point increase in their average pain score at the follow-up period. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained the subject's pain relief. The frequency and percentage of subjects' that maintained their average baseline VAS pain score were reported at each amplitude level.

    Time frame: 8 weeks

07

Results

Posted Mar 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneSpinal Cord Stimulation
Started30
Completed30
Not completed0

Outcome measures

PrimarySCS Therapy Satisfaction

To characterize the effect of four different amplitude settings on baseline SCS therapy satisfaction. At each follow-up visit, the following question was asked to measure satisfaction: "Overall how satisfied or unsatisfied are you with this therapy?". The response choices were as follows: "very satisfied", "somewhat satisfied", "neutral", "somewhat unsatisfied", "very unsatisfied". Each subject was considered to have maintained their baseline SCS therapy satisfaction if they selected the response "very satisfied", "somewhat satisfied", or "neutral", otherwise they were considered dissatisfied with the therapy. The first visit in which each subject reported dissatisfaction of the therapy was recorded. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained each subject's therapy satisfaction. The frequency and percentage of subjects' that maintained baseline satisfaction were reported at each amplitude level.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
SCS Therapy Satisfaction
ParticipantsSpinal Cord Stimulation
Baseline6
80% perception threshold2
60% perception threshold1
40% perception threshold0
20% perception threshold21
SecondaryNumber of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)

To characterize the effect of four different amplitude settings on baseline pain relief. During each follow-up period the VAS pain score was recorded once a day, on a multi-day diary, where subjects rated their pain by making a vertical slash mark through the 0-10 cm line that best described their pain during the last 24 hours, with 0 = No pain and 10 = Worst pain imaginable. The higher VAS pain score represented worse pain. The average VAS pain scores from the last 3 days of the diary prior to the scheduled visit was used for analysis. Each subject was considered to have maintained their baseline pain if there was less than a 2 point increase in their average pain score at the follow-up period. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained the subject's pain relief. The frequency and percentage of subjects' that maintained their average baseline VAS pain score were reported at each amplitude level.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)
ParticipantsSpinal Cord Stimulation
Baseline5
80% perception threshold3
60% perception threshold1
40% perception threshold2
20% perception threshold19

Adverse events

Collected over Adverse events were collected from enrollment to study discontinuation with an average of 2.2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Spinal Cord Stimulation0/30 (0%)0/30 (0%)5/30 (16.7%)
Most frequent other events
Most frequent other events
EventSpinal Cord Stimulation
Device stimulation issueProduct Issues3/30
Inadequate analgesiaGeneral disorders1/30
Back painMusculoskeletal and connective tissue disorders1/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Spinal Cord Stimulation
Mean65.1 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Spinal Cord Stimulation
Female23
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Spinal Cord Stimulation
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White30
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Spinal Cord Stimulation
United States30
08

Study locations

10 sites
  • Arizona Pain Doctors
    Chandler, Arizona 85224, United States
  • Georgia Pain and Wellness Center
    Lawrenceville, Georgia 30046, United States
  • Global Scientific Innovations
    Evansville, Indiana 47714, United States
  • Goodman Campbell Brain and Spine
    Indianapolis, Indiana 46202, United States
  • Kentuckiana Pain Specialists
    Louisville, Kentucky 40241, United States
  • Drez One, LLC
    Somerset, Kentucky 42503, United States
  • Regional Brain & Spine
    Cape Girardeau, Missouri 63701, United States
  • Precision Spine Care
    Tyler, Texas 75701, United States
  • Northwest Pain Care, Inc.
    Spokane, Washington 99201, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2019, 16 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 15 phase 4 interventional studies under Back Pain, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 40. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2017
First posted
Sep 15, 2017
StartActual
Nov 1, 2017
Primary completionActual
Mar 15, 2019
CompletionActual
Mar 15, 2019
Results first posted
Mar 18, 2020
Last update
Apr 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03284411
Lead sponsor
MedtronicNeuro
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
Nov 1, 2017
Primary completion
Mar 15, 2019
Completion
Mar 15, 2019
Results posted
Mar 18, 2020
Last update
Apr 15, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion